Arne Scheu
About Arne Scheu
Arne Scheu is the CEO and founder of LiliumX, known for his significant contributions to protein engineering and novel therapeutics.
Arne Scheu: CEO, Founder of LiliumX
Arne Scheu is the CEO and founder of LiliumX, where he guides the company's strategic direction and innovation in the field of protein engineering and therapeutics. His leadership is defined by a robust blend of scientific know-how and entrepreneurial drive, which he applies to advance novel bioengineering solutions. Through LiliumX, Scheu focuses on pioneering the development and commercialization of cutting-edge therapeutic technologies.
Arne Scheu's Education and Expertise
Arne Scheu completed his Doctor of Philosophy (DPhil) at the University of Oxford, where he was a Rhodes Scholar. His academic background is rooted in advanced research, having focused on the development of a novel technology for stable modification of endogenous proteins. This expertise forms the basis of his work in protein engineering, a field in which he strives to deliver innovative therapeutic solutions.
Arne Scheu's Research Background
Arne Scheu's prior research revolves around the stable modification of endogenous proteins. This work is crucial to the advancement of bioengineering and pharmaceuticals, providing a stable and reliable method for protein modifications which are integral to the development of new drugs and therapies. Scheu's research underpinning his current work at LiliumX underscores his commitment to the practical application of scientific discoveries.
Arne Scheu at the 14th World Bispecific Summit 2023
Arne Scheu presented at the 14th World Bispecific Summit held from October 2-4, 2023, in Boston. During this event, he showcased LiliumX's Universal Assembly Platform™ for rapid antibody engineering. His talk covered the exciting potential of cis-acting drugs to offer novel mechanisms of action, and highlighted LiliumX’s innovative modular approach to drug candidate assembly. His presentation was recognized as a significant contribution to the field.
LiliumX's Universal Assembly Platform™ and Bispecific ADCs
Arne Scheu unveiled the Universal Assembly Platform™ by LiliumX at the Novel Formats of Multispecifics Seminar. This platform enables the rapid engineering of antibodies and is key to the discovery of bispecific antibody-drug conjugates (ADCs). By combining multispecific and multivalency properties with antibody-drug conjugation, this platform integrates complex drug discovery processes into a streamlined approach, signaling a significant advancement in the creation of therapeutic candidates.